Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Remegen Co Ltd (9995)
Remegen Co Ltd stock price live, this page displays HK 9995 stock exchange data. View the 9995 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Remegen Co Ltd real time stock price chart below.
What Is the Remegen Co Ltd Stock Price Today?
The Remegen Co Ltd stock price today is 100.60.
What Is the Stock Symbol for Remegen Co Ltd?
The stock symbol for Remegen Co Ltd is "9995."
What Stock Exchange Does Remegen Co Ltd Trade On?
Remegen Co Ltd is listed and trades on the Hong Kong stock exchange.
Is Remegen Co Ltd a Good Stock to Buy?
Determining whether Remegen Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9995 quote. (ISIN: CNE1000048G6)
What Is the Remegen Co Ltd Stock Price Today?
The Remegen Co Ltd stock price today is 100.60.
What Is the Stock Symbol for Remegen Co Ltd?
The stock symbol for Remegen Co Ltd is "9995."
What Stock Exchange Does Remegen Co Ltd Trade On?
Remegen Co Ltd is listed and trades on the Hong Kong stock exchange.
Is Remegen Co Ltd a Good Stock to Buy?
Determining whether Remegen Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9995 quote. (ISIN: CNE1000048G6)
100.60
+0.50(+0.50%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
98.50
103.50
52 wk Range
35.15
126.60
9995 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
98.50103.50
52 wk Range
35.15126.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
9995 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
111.40
Upside
+10.74%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
13 Buy
4 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 111.40
(+10.74% Upside)
Earnings
Latest Release
Oct 30, 2025
EPS / Forecast
-0.18 / --
Revenue / Forecast
621.88M / --
Compare 9995 to Peers and Sector
Metrics to compare | 9995 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9995PeersSector | |
|---|---|---|---|---|
P/E Ratio | 49.9x | −21.6x | −0.5x | |
PEG Ratio | 0.26 | 0.09 | 0.00 | |
Price/Book | 16.4x | 6.1x | 2.6x | |
Price / LTM Sales | 19.1x | 20.0x | 3.2x | |
Upside (Analyst Target) | 19.6% | 33.6% | 50.8% | |
Fair Value Upside | Unlock | 5.0% | 7.7% | Unlock |
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Remegen (9995) Stock Price Today?
The Remegen stock price today is 100.60 HKD.
What Stock Exchange Does Remegen Trade On?
Remegen is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Remegen?
The stock symbol for Remegen is "9995."
What Is the Remegen Market Cap?
As of today, Remegen market cap is 73.85B HKD.
What Is Remegen's Earnings Per Share (TTM)?
The Remegen EPS (TTM) is 2.33.
From a Technical Analysis Perspective, Is 9995 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Remegen Stock Split?
Remegen has split 0 times.
How Many Employees Does Remegen Have?
Remegen has 3048 employees.
What is the current trading status of Remegen (9995)?
As of Apr 30, 2026, Remegen (9995) is trading at a price of 100.60 HKD, with a previous close of 100.10 HKD. The stock has fluctuated within a day range of 98.50 HKD to 103.50 HKD, while its 52-week range spans from 35.15 HKD to 126.60 HKD.
What Is Remegen (9995) Price Target According to Analysts?
The average 12-month price target for Remegen is 111.40 HKD, with a high estimate of 144.71222197 HKD and a low estimate of 52.53152947 HKD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +10.74% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.